Effect of CpG Oligodeoxynucleotides on the Immunogenicity of Pfs25, a Plasmodium falciparum Transmission-Blocking Vaccine Antigen

Infection and Immunity

Volumn 72, Issue 1, 2004, Pages 584-588

  Coban, Cevayir ^a   Ishii, Ken J ^b   Stowers, Anthony W ^c,d   Keister, David B ^c   Klinman, Dennis M ^b   Kumar, Nirbhay ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d CSL LIMITED   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MALARIA VACCINE; OLIGODEOXYNUCLEOTIDE; PROTEIN; PROTEIN PFS25; PROTOZOAL VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CPG ISLAND; DISEASE TRANSMISSION; DRUG EFFECT; GAMETOCYTE; IMMUNOGENICITY; IMMUNOMODULATION; LIFE CYCLE; MALARIA; MOSQUITO; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTOZOAL INFECTION; SPOROZOITE;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY AFFINITY; IMMUNIZATION; IMMUNIZATION, SECONDARY; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 0348141892     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.72.1.584-588.2004     Document Type: Article

References (36)

1. Barr, P. J., K. M. Green, H. L. Gibson, I. C. Bathurst, I. A. Quakyi, and D. C. Kaslow. 1991. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J. Exp. Med. 174:1203-1211.
2. Carter, R., P. M. Graves, D. B. Keister, and I. A. Quakyi. 1990. Properties of epitopes of Pfs 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum. Parasite Immunol. 12:587-603.
3. Carter, R., P. M. Graves, I. A. Quakyi, and M. F. Good. 1989. Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies. J. Exp. Med. 169:135-147.
4. Chu, R. S., O. S. Targoni, A. M. Krieg, P. V. Lehmann, and C. V. Harding. 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1623-1631.
5. Coban, C., K. J. Ishii, D. J. Sullivan, and N. Kumar. 2002. Purified malaria pigment (hemozoin) enhances dendritic cell maturation and modulates the isotype of antibodies induced by a DNA vaccine. Infect. Immun. 70:3939-3943.
6. Coban, C., M. T. Philipp, J. E. Purcell, D. B. Keister, M. Okulate, D. S. Martin, and M. Kumar. 2004. Induction of Plasmodium falciparium transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect. Immun. 72:253-259.
7. Duffy, P. E., and D. C. Kaslow. 1997. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect. Immun. 65:1109-1113.
8. Gozar, M. M., V. L. Price, and D. C. Kaslow. 1998. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect. Immun. 66:59-64.
9. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, S. Akira, and P. Moingeon. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745. (Erratum, 409:646, 2001.)
10. Hirunpetcharat, C., J. Wipasa, S. Sakkhachornphop, T. Nitkumhan, Y. Z. Zheng, S. Pichyangkul, A. M. Krieg, D. S. Walsh, D. G. Heppner, and M. F. Good. 2003. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. Vaccine 21:2923-2932.
11. Ishii, K. J., F. Takeshita, I. Gursel, M. Gursel, J. Conover, A. Nussenzweig, and D. M. Klinman. 2002. Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J. Exp. Med. 196:269-274.
12. Jones, T. R., N. Obaldia III, R. A. Gramzinski, Y. Charoenvit, N. Kolodny, S. Kitov, H. L. Davis, A. M. Krieg, and S. L. Hoffman. 1999. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 17:3065-3071.
13. Kaslow, D. C. 1993. Transmission-blocking immunity against malaria and other vector-borne diseases. Curr. Opin. Immunol. 5:557-565.
14. Kaslow, D. C., and J. Shiloach. 1994. Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Bio/Technology 12:494-499.
15. Kaslow, D. C., I. A. Quakyi, C. Syin, M. G. Raum, D. B. Keister, J. E. Coligan, T. F. McCutchan, and L. H. Miller. 1988. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333:74-80.
16. Kaslow, D. C., I. C. Bathurst, T. Lensen, T. Ponnudurai, P. J. Barr, and D. B. Keister. 1994. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect. Immun. 62:5576-5580.
17. Kaslow, D. C., S. N. Isaacs, I. A. Quakyi, R. W. Gwadz, B. Moss, and D. B. Keister. 1991. Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus. Science 252:1310-1313.
18. Klinman, D. M., D. Verthelyi, F. Takeshita, and K. J. Ishii. 1999. Immune recognition of foreign DNA: a cure for bioterrorism? Immunity 11:123-129.
19. Klinman, D. M., J. Conover, and C. Coban. 1999. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect. Immun. 67:5658-5663.
20. Klinman, D. M., K. M. Barnhart, and J. Conover. 1999. CpG motifs as immune adjuvants. Vaccine 17:19-25.
21. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760.
22. Kumar, N., I. Ploton, G., Koski, C. Ann-Lobo, and C. Contreras. 1995. Malaria transmission-blocking immunity. Identification of epitopes and evaluation of immunogenicity. Adv. Exp. Med. Biol. 383:65-72.
23. Lobo, C. A., R. Dhar, and N. Kumar. 1999. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Infect. Immun. 67:1688-1693.
24. McCluskie, M. J., and H. L. Davis. 1998. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161:4463-4469.
25. McCluskie, M. J., and H. L. Davis. 2000. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19:413-422.
26. Moldoveanu, Z., L. Love-Homan, W. Q. Huang, and A. M. Krieg. 1998. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16:1216-1224.
27. Near, K. A., A. W. Stowers, D. Jankovic, and D. C. Kaslow. 2002. Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model. Infect. Immun. 70:692-701.
28. O'Hagan, D. T., M. L. MacKichan, and M. Singh. 2001. Recent developments in adjuvants for vaccines against infectious diseases. Biomol. Eng. 18:69-85.
29. Quakyi, I. A., R. Carter, J. Rener, N. Kumar, M. F. Good, and L. H. Miller. 1987. The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. J. Immunol. 139:4213-4220.
30. Roeffen, W., F. Geeraedts, W. Eling, P. Beckers, B. Wizel, N. Kumar, T. Lensen, and R. Sauerwein. 1995. Transmission blockade of Plasmodium falciparum malaria by anti-Pfs230-specific antibodies is isotype dependent. Infect. Immun. 63:467-471.
31. Sano, K., H. Shirota, T. Terui, T. Hattori, and G. Tamura. 2003. Oligodeoxynucleotides without CpG motifs work as adjuvant for the induction of Th2 differentiation in a sequence-independent manner. J. Immunol. 170:2367-2373.
32. Stowers, A., and R. Carter. 2001. Current developments in malaria transmission-blocking vaccines. Expert Opin. Biol. Ther. 1:619-628.
33. Stowers, A. W., D. B. Keister, O. Muratova, and D. C. Kaslow. 2000. A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies. Infect. Immun. 68:5530-5538.
34. Takeshita, F., C. A. Leifer, I. Gursel, K. J. Ishii, S. Takeshita, M. Gursel, and D. M. Klinman. 2001. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167:3555-3558.
35. Wagner, H. 1999. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv. Immunol. 73:329-368.
36. Weeratna, R. D., M. J. McCluskie, Y. Xu, and H. L. Davis. 2000. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18:1755-1762.